Information  X 
Enter a valid email address

Hemogenyx Pharma Plc (HEMO)

  Print      Mail a friend

Thursday 07 December, 2017

Hemogenyx Pharma Plc

Result of AGM

RNS Number : 7127Y
Hemogenyx Pharmaceuticals PLC
07 December 2017
 

 

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

 

Result of AGM

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that at its Annual General Meeting held today, all resolutions were duly passed.

 

Enquiries:

 

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Dr Robin Campbell, Chairman




Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 




Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar




Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey




Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893



 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFSLFEWFWSEFE

a d v e r t i s e m e n t